Combination of first-line chemotherapy with Kanglaite injections versus first-line chemotherapy alone for advanced non-small-cell lung cancer: study protocol for an investigator-initiated, multicenter, open-label, randomized controlled trial

Ruike Gao1,2†, Ying Zhang1†, Wei Hou1, Jie Li1*, Guanghui Zhu1,3, Xiaoxiao Zhang1,2, Bowen Xu1,3, Zhe Wu1,2 and Heping Wang1,2

Abstract

Background: Non-small-cell lung cancer (NSCLC) is usually diagnosed at an advanced stage, and chemotherapy is the main treatment for this disease. Kanglaite injections (KLTi) have been widely used for the treatment of cancer in China. KLTi combined with chemotherapy could improve the short-term efficacy, quality of life, and performance status for NSCLC compared with chemotherapy alone. This trial aims to assess the long-term efficacy and safety of KLTi in combination with chemotherapy for the treatment of advanced NSCLC.

Methods: This will be an investigator-initiated multicenter open-label randomized controlled trial. We will randomly assign 334 eligible participants with stage IIIA-IV NSCLC to the treatment or control groups in a 1:1 ratio. Patients in both groups will be administered 4–6 cycles of first-line platinum-based double chemotherapy regimens. Patients with complete response, partial response, or stable disease after 4–6 cycles will receive non-platinum single-agent chemotherapy. Patients in the treatment group are to receive intravenous KLTi 200 ml per day continuously for 14 days, commencing on the first day of chemotherapy. The treatment will be discontinued at the time of disease progression or until unacceptable toxicity is noted. The follow-up will be conducted every 2 months until death, loss of follow-up, or 12 months from randomized enrollment. The primary outcome will be progression-free survival (PFS). The secondary outcomes will be the objective response rate, 1-year survival rate, quality of life, living ability, and blood lipids. The safety outcome will be the rate of adverse events.

(Continued on next page)
Drugs showed improved efficacy in NSCLC patients with combination of chemotherapy and molecular targeted cisplatin-based combination chemotherapy [11, 12]. Negative genetic mutations are routinely treated with systemic chemotherapy remains an important component of the advanced NSCLC treatment. Patients with negative genetic mutations are routinely treated with cisplatin-based combination chemotherapy [11, 12]. A combination of chemotherapy and molecular targeted drugs showed improved efficacy in NSCLC patients with certain genetic mutations [13–15]. Specifically, cisplatin-based combination chemotherapy regimen has been used as a standard treatment after the failure of targeted therapy and prolongs survival in NSCLC patients [16, 17]. Furthermore, chemotherapy combined with ICIs showed encouraging antitumor results [18, 19]. However, most chemotherapeutic agents have severe AEs that drastically affect the patient’s quality of life. Moreover, the use of chemotherapeutic agents is associated with drug resistance [20]. Therefore, there is an urgent need for new improved treatment strategies.

Traditional Chinese medicine (TCM) has been used to reduce the side effects of cancer chemotherapy and improve the effects of treatment. Previous findings have shown that TCM, combined with chemotherapy prolonged the survival in patients with advanced NSCLC, improved patient symptoms and reduced chemotherapy-related side effects [21–23]. Kanglaite injection (KLTi), an intravenous TCM modality, has been used to treat millions of patients with cancer since 1997 [24, 25]. KLTi is a microemulsion of Coix seed oil extracted from Semen Coicis, a traditional Chinese medicinal plant, which has demonstrated immunomodulatory effects and antitumor activities [24, 26]. Previous studies have shown that KLTi promoted tumor cell apoptosis by upregulating the expression of the p53 and FAS genes, as well as Caspase-3, proliferating-cell nuclear antigen (PCNA), and p21WAFI/CIPI, and by downregulating the expression of the cyclin A, cyclin E1, and cyclin F coding genes [27]. It can also suppress tumor growth by inhibiting the activity of protein kinase C and NF-κB signaling [28]. Moreover, some studies have demonstrated that KLTi had antitumor and immunostimulatory activities in C57BL/6 mice with Lewis lung carcinoma [29]. A recent meta-analysis found that KLTi in combination with chemotherapy improved clinical efficacy, quality of life, and reduced the incidence of AEs compared with chemotherapy alone in patients with advanced NSCLC [30–33]. However, previous research has mainly focused on short-term efficacy and toxicity, and there is a lack of data on long-term survival outcomes. The use of Coix seed oil is associated with a reduction in blood lipids [34]. KLTi can significantly suppress proliferation and induce apoptosis and differentiation in 3T3-L1 preadipocyte cells without affecting food intake [26]. However, there is no clinical data to evaluate the effect of KLTi on lipid profiles.

Therefore, this study aimed to investigate the long-term efficacy and safety of KLTi combined with first-line chemotherapy in advanced NSCLC. We also sought to obtain clinical evidence to determine the effect of KLTi on lipid profiles.

**Method/design**

**Study design**

This study is a multicenter, randomized, open-label clinical trial with two parallel arms. The purpose is to estimate the effectiveness and safety of KLTi in patients with advanced NSCLC who have not received anticancer treatment prior to participation in this study. Eligible participants will be randomly assigned to either the treatment or control group using an online tool. Patients in the treatment group...
will receive KLTi combined with first-line chemotherapy and those in the control group will receive first-line chemotherapy alone. Eligible patients will receive therapy continuously until either disease progression according to the Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) [35], unacceptable toxicity, completion of 12 months starting from the time of randomized enrollment, or withdrawal of informed consent. After disease progression, follow-up will be conducted every 2 months until death, loss of follow-up, or 12 months from randomized enrollment. The flow chart of the study design is shown in Fig. 1. This protocol has been registered on Clinical Trials (ClinicalTrials.gov, ID: NCT03986528).

Eligibility criteria
The inclusion criteria will be as follows:

- A histologically or cytologically confirmed diagnosis of Stage III-IV NSCLC, with no history of anticancer treatment including chemotherapy;
- Male or female aged 18–75 years;
- Eastern Cooperative Oncology Group (ECOG) performance score 0–2;
- Life expectancy of at least 3 months;
- At least one radiographically measurable lesion as per RECIST 1.1;
- Willing to join the clinic trial and sign the informed consent;
- Able to comply with scheduled visits and treatments.

The exclusion criteria will be as follows:

- Presence of cerebral metastases;
- Confirmed positive for expression of epidermal growth factor receptor (EGFR), activin receptor-like

![Flow chart of the study](image)

*Fig. 1 Flow chart of the study. KLTi, Kanglaite injection; PFS, progression-free survival; ORR, objective response rate*
kinase (ALK), c-ros oncogene 1 (ROS1) mutation, or programmed death-ligand 1 (PD-L1) (tumor proportion score [TPS] ≥ 50%) in a genetic test;
(3) Participants with malignant pleural effusion underwent intrapleural injection chemotherapy;
(4) Currently undergoing or preparing for treatment with target therapy;
(5) Currently undergoing or preparing for radiotherapy treatment to the thorax;
(6) Currently undergoing or preparing for treatment with tumor immunotherapy;
(7) Currently undergoing lipid-decreasing treatment;
(8) Pregnant or breastfeeding women;
(9) Fertile patients who are unwilling or unable to take effective contraceptive measures during the research period until 6 months after the study end date;
(10) A history of mental disorders;
(11) Severe and uncontrolled organic lesion or infection, including but not limited to cardiopulmonary failure and renal failure, which lead to poor tolerance of chemotherapy;
(12) Participated in other clinical trials of small molecule research drugs within 28 days prior to enrollment, or participated in other clinical trials of large molecule research drugs within 3 months before enrollment;
(13) Known allergy or intolerance to study medications;
(14) Considered to be otherwise unsuitable for the clinical study by researchers.

Interventions
Eligible patients will be randomized 1:1 to the treatment or control group. Patients in both groups will receive 4–6 cycles of first-line platinum-based double chemotherapy regimens. Patients with complete response (CR), partial response (PR), or stable disease after 4–6 cycles will receive non-platinum single-agent chemotherapy. The chemotherapy regimens are in accordance with the National Comprehensive Cancer Network (NCCN) guidelines (2019.V3) [36] (Table 1). Patients in the treatment group are to receive intravenous KLTi 200 ml per day continuously for 14 days, commencing on the first day of chemotherapy. In this study, treatment will be discontinued if one or more of the following occurs: (1) unacceptable toxicity; (2) withdrawal of informed consent; (3) tumor progression; or (4) completion of 12 months starting from the time of randomized enrollment. Treatment for other conditions, such as hypertension, diabetes mellitus, and other chronic diseases, will be permitted during protocol treatment. However, anti-angiogenic agents, other TCM injections, Chinese patent medicines with antitumor effects, and other antitumor methods are prohibited for all patients during the treatment course.

KLTi (specifications: 100 ml/tube) will be manufactured by Zhejiang Kanglaite Pharmaceutical Co. Ltd. (Hangzhou, China). Tumor response assessment will be performed every 6–8 weeks during protocol treatment using the RECIST guidelines (version 1.1) [35].

Outcome measures

Primary outcome
Progression-free survival (PFS) The primary outcome is PFS, which will be measured every 41–56 days (2 cycles) from the randomization to the onset of disease progression or death, whichever comes first. Patients without progression at the cutoff date will be censored on the date of the last contact.

Secondary outcomes
Objective response rate (ORR) The ORR is the percentage of participants who have a complete response (CR), defined as the disappearance of all target lesions or a partial response (PR), defined as ≥ 30% decrease in the sum of the diameters of target lesions as assessed by RECIST 1.1 [35]. This will be evaluated every 41–56 days (2 cycles) until disease progression, death, or 12 months after randomized enrollment.

One-year survival rate The 1-year survival rate refers to the proportion of patients with a survival period of more than 1 year starting from randomized enrollment.

| Table 1 Chemotherapy regimens for NSCLC |
|-----------------------------------------|
| **Pathologic types** | **Chemotherapy regimen** | **Dosage (mg/m²)** | **Medication time** |
|-----------------------|--------------------------|---------------------|---------------------|
| Squamous cell carcinoma | GC | Gemcitabine 1000 | D1, 8 |
| | | Cisplatinum 75 | D1–3 |
| | GC | Gemcitabine 1000 | D1, 8 |
| | | Carboplatin | AUC = 6 |
| Adenocarcinoma, large cell, NSCLC not otherwise specified (NOS) | PP | Pemetrexed 500 | D1 |
| | | Cisplatinum 75 | D1–3 |
| | PC | Pemetrexed 500 | D1 |
| | | Carboplatin AUC = 6 | D1 |

Notes: If patients experience gemcitabine-associated intolerable toxicities, paclitaxel will be used instead of gemcitabine. The dose of paclitaxel is 135 mg/m² D1. The dosages of the chemotherapy regimens are provided only for reference, and specific implementation will take clinical application as a standard.

AUC area under the curve, NSCLC non-small cell lung cancer
**Randomization**

Random assignment of eligible patients using the minimization technique will be performed through a web-based central randomization system, which will be operated by one physician in each center. This system ensures the allocation sequence unpredictable. Patients will be assigned to either the treatment or the control group (1:1) according to gender (female vs. male), age (>60 vs. ≤60 years old), adenocarcinoma (yes vs. no), and staging (stage III vs. IV).

**Data collection and management**

The data of all participants including those who will be discontinued or deviated from intervention protocols will be collected according to study protocol. Frequent follow-up phone call will be conducted to promote participant retention.

The case report forms (CRFs) will be used to collect data. To ensure that all data recorded in the CRFs is consistent with the original material, a CRC will be assigned to assist physicians to document and manage all visits and examinations. To ensure the timeliness of the data, the CRFs must be completed within 3 days of each visit.

An online web-based electronic data capture system will also be used for data collection and management. Double data entry is employed and performed by two independent researchers. The modified data will be highlighted in red. Patients will be identified on the electronic CRF (e-CRF) using initials and a unique code.

Confidentiality procedures are outlined on the consent form. All CRFs will be kept in locked cabinets. Only the research team will have access to the data.

**Blood sample collection and management**

Peripheral venous blood samples (10.5 ml) will be collected under fasting conditions before chemotherapy infusion at baseline and every 2 cycles for up to 12 months after randomized enrollment or until withdrawal.
of informed consent, tumor progression, or death. Each blood sample (10.5 ml) will be divided into three fractions: 2 ml blood collected in an EDTA tube, 6 ml blood collected in an EDTA tube to obtain plasma, and 2.5 ml blood collected in a PAXgene Blood RNA tube. All collected samples will be stored anonymously at −80°C in the Cancer Laboratory of Guang’anmen Hospital. A specially assigned person will be in charge of the management of blood samples. Informed consent from each participant will be obtained before blood collection. The blood samples will be analyzed for multi-omics analysis in the current trial and for future use in ancillary studies.

Quality control
On-site training will be carried out before the initiation of the study. This will enable the study physicians, nurses, and quality control personnel to fully apprehend the process of the entire trial. Any questions will be answered in a timely manner by the central study team. When disease progression occurs, the doctor-in-charge and chief physician will evaluate patient conditions based on imaging studies and will fill out the assessment form.

Three levels of quality control will be performed: a data manager and research secretary for each participating unit (first-level), a CRC and clinical research associate (CRA) of Beijing Kangpaite Medical Science and Technology Development Co., Ltd. (second-level), and six supervisors from the central research group (third-level). Subjects will be enrolled after the doctor-in-charge, CRC, CRA, and a trained oncologist from the central research group check the patient information against the inclusion and exclusion criteria. During the study, the CRC, CRA, and the supervisors from the central research group will carry out regular site visits to review protocol compliance, conduct source data verification, and assess drug accountability and management and trial procedures. They will also ensure that the study is being conducted according to the relevant regulatory and protocol requirements. The supervisors from the central research group also will regularly monitor the quality of the data obtained by the electronic data capture system.

Statistical analysis
An independent, professional statistician will process the data for the results and the AEs using SAS 9.2 statistical software. P values < 0.05 will be considered statistically significant.

Data will be cross-checked for outliers and missing values. Outliers will be removed after data analysis, and missing values will be handled using carry forward methodology or considered for drop-out after data analysis. The measurement data will be described by mean, standard deviation, median, minimum, and maximum.

| Number | Hospital name                                                                 | Region (in China) |
|--------|-------------------------------------------------------------------------------|-------------------|
| 01     | Guang’anmen Hospital, China Academy of Chinese Medical Science                 | Beijing           |
| 02     | The First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine | Shenyang          |
| 03     | The First Affiliated Hospital of Guangzhou University of Chinese Medicine      | Guangzhou         |
| 04     | The Affiliated Hospital of Shandong University of Traditional Chinese Medicine | Jinan             |
| 05     | Jiangsu Province Hospital of Chinese Medicine                                  | Nanjing           |
| 06     | Shanxi Provincial Cancer Hospital                                             | Taiyuan           |
| 07     | Tianjin Medical University Cancer Institute & Hospital                        | Tianjin           |
| 08     | Hunan Provincial Tumor Hospital                                               | Changsha          |
| 09     | Hunan Academy of Traditional Chinese Medicine Affiliated Hospital             | Changsha          |
| 10     | Gansu Provincial Tumor Hospital                                               | Lanzhou           |
| 11     | The Fourth Military Medical University Tangdu Hospital                        | Xian              |
| 12     | Anhui Chest Hospital                                                          | Hefei             |
| 13     | Chongqing Cancer Hospital                                                     | Chongqing         |
| 14     | Zhengzhou Cancer Hospital                                                     | Zhengzhou         |
| 15     | The First Affiliated Hospital of Zhejiang Chinese Medicine University          | Hangzhou          |
| 16     | XuZhou Central Hospital                                                        | XuZhou            |
| 17     | Longhua Hospital Shanghai University of Traditional Chinese Medicine          | Shanghai          |
| 18     | Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine | Shanghai          |
The enumeration data will be expressed in frequency counts and percentages. PFS is the primary outcome and will be analyzed using the Kaplan-Meier method and compared between the two groups using the log-rank test. A stratified Cox proportional-hazards model and Efron’s method of tie handling will be used to assess the magnitude of the difference between the trial groups. We will use the chi-square test to compare the 1-year survival rate and ORR between treatment and control groups. Changes in CHO, TG, HDL-C, LDL-C, and the questionnaire scores of EORTC QLQ-C30 and LCSS will be assessed using paired sample t-test, Wilcoxon rank-sum test, or independent t-test.

Discussion
Kanglaite, a type of Chinese herb product extracted from the Coix seed, is a microemulsion and has been used as an antitumor drug in China for many years. This study aims to explore the long-term efficacy and safety of KLTi combined with first-line chemotherapy for the treatment of advanced NSCLC.

In the previous studies of KLTi on advanced NSCLC, the primary endpoint was ORR, which was evaluated after 2 or 4 treatment cycles. But it cannot fully determine the clinical benefits of the trial drug. Overall survival (OS) is the gold standard marker of efficacy for any cancer treatment [43]. However, taking OS as the primary endpoint prolongs the study observation period, and the results may easily be affected by cross-treatment and follow-up treatments. Therefore, determining a surrogate endpoint for OS has been the subject of much discussion in recent years. Guidelines from both the European Medicines Agency (EMEA) and the United States Food and Drug Administration (FDA) describe PFS as an endpoint that may be used to demonstrate clinical benefit [44]. In operable NSCLC (adjuvant trials) and locally advanced NSCLC (radiotherapy trials), Mauguen et al. reported a high correlation between DFS/PFS and OS at the patient and trial level [45]. In addition, the magnitude of advantage in tumor response is suggested to contribute to a better prediction of OS-HR based on PFS-HR in clinical trials in patients with advanced NSCLC [46]. Accordingly, PFS is the primary endpoint in this study.

Some studies have found that there was a strong link between serum lipids and morbidity and mortality in certain types of cancer, including gastric cancer, gastrointestinal malignancies, and prostate cancer [47–49]. Furthermore, a study of blood lipid profiles and lung cancer risk in a meta-analysis on prospective cohort studies showed that levels of both serum HDL-C and TC were significantly inversely correlated with the incidence of lung cancer. In contrast, serum TG levels showed a significant positive correlation with lung cancer incidence. Coix seed oil is known to reduce blood lipids [34], and KLTi has been associated with a decrease in the lung cancer-promoting effects of high-fat diet (HFD)-induced obesity [26]. Therefore, this study will monitor the blood lipid profiles, including TC, HDL-C, LDL-C, and TG, to explore the effect of KLTi on blood lipids.

The placebo of KLTi is difficult to access in China, and it is therefore impossible to blind the study. To reduce this bias, all of the participating hospitals are tertiary grade A hospitals in China, with the same level of diagnosis and treatment. In addition, the doctor-in-charge and a chief physician will evaluate the condition of each subject when the disease progresses. Finally, to guarantee the reliability of the results of this study, we will adopt quality control measures for four different aspects: (i) training of researchers before the start of the project, (ii) management of enrolled patients, (iii) perform three levels of quality control, and (iv) online and offline monitoring of data.

We expect that this trial will provide a high degree of evidence for the efficacy and safety of KLTi combined with chemotherapy in treating advanced NSCLC. In addition, the blood lipid results will allow us to assess the effects of KLTi on blood lipids.

Trial status
The trial was prospectively registered at ClinicalTrials.gov (ID: NCT03986528) on May 30, 2019. Recruitment began in August 28, 2019. Expected date when recruitment will be completed in December, 2020. Due to COVID-19, the recruitment is expected to end in December 2021. Analysis of the primary outcome measure will be completed in March, 2022. The study will end in May, 2022.

Abbreviations
NSCLC: Non-small-cell lung cancer; KLTi: Kanglaite injections; TCM: Traditional Chinese medicine; PFS: Progression-free survival; OS: Overall survival; ORR: Objective response rate; RECIST 1.1: The Response Evaluation Criteria in Solid Tumors 1.1; ECOG: Eastern Cooperative Oncology Group (ECOG); EGFR: Epidermal growth factor receptor; ALK: Activin receptor-like kinase; ROS1: c-ros oncogene 1; PD-L1: Programmed death-ligand 1; NCCN: National Comprehensive Cancer Network; CR: Complete response; PR: Partial response; EORTC: European Organization for Research and Treatment of Cancer; QLQ-C30: Quality of Life Questionnaire Core 30; LCSS: Lung Cancer Symptom Scale; KPS: Karnofsky performance status; TC: Total cholesterol; TG: Triglyceride; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; AE: Adverse events; CTCAE v4.03: National Cancer Institute’s Common Terminology Criteria for Adverse Events v4.03; EMEA: European Medicines Agency; FDA: Food and Drug Administration

Acknowledgements
We are grateful to Ms. Zhaolan Liu for her assistance in with the statistical design, and to every researcher in the 18 study hospitals for their advice and hard work in the future. We also would like to thank Editage (www.editage.cn) for English language editing.
Authors’ contributions

JL, YZ, and WH participated in the design and coordination of the study. JL and YZ designed the study protocol. YZ and RKG were in charge of study coordination. GHZ, ZXX, and BXW supervised patient recruitment. YZ helped to develop the study measures and analyses. RKG drafted the manuscript. HPW and ZW helped to draft the manuscript. All authors have read and approved the final manuscript.

Funding

This study is supported by the National Key Research and Development Project of China, grant number 2018YFC1707405. The funding source had no role in the design of this study and will not have any role during the execution, analyses, interpretation of the data, or writing the manuscript.

Availability of data and materials

The results of the study will be issued to publications through scientific journals and conference reports. The anonymized datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

The study protocol and consent process are both approved by the ethics committee of Guang’anmen Hospital, China Academy of Chinese Medical Science (approval #: 2019-068-KY). Ethics approval will additionally be obtained from each participating hospital. The study is designed to comply with the Declaration of Helsinki, Good Clinical Practice guidelines, and local laws and regulations. Every amendment in the research protocol will be first submitted to the Ethics Committee for approval.

Before participating, each patient will sign and date an informed consent form. Consent includes the option to give permission for collect peripheral venous blood for multi-omics analysis and for the use of samples in future studies. Patients or their surrogates will sign the informed consent form in duplicate and keep one of the copies; other related documentation will be available from the corresponding author on request.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China. 2China Academy of Chinese Medical Sciences, Beijing, China. 3Beijing University of Chinese Medicine, Beijing, China.

Received: 14 June 2020 Accepted: 4 March 2021

Published online: 17 March 2021

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(2):394–424.

2. Miller KD, Noone AM, Ostrzenski J, Seru A, Sause W, Hankey BF, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363–85. https://doi.org/10.3322/caac.21565.

3. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer: EUSOMA Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv2–17.

4. Shaw AT, Kim DW, Nakagawa K, Seto T, Sun X, Ahn MJ, et al. Crizotinib for advanced non-small-cell lung cancer: phase 1 cohorts from the KEYNOTE-016/j.ctarc.2016.07.005.

5. McDermott D, Sznol M, Marmont E, Pathak A, et al. Pembrolizumab versus chemotherapy as first-line therapy for advanced non-small-cell lung cancer. J Clin Oncol. 2018;36(21):2149–56. https://doi.org/10.1200/JCO.2017.75.1944.

6. Shaw AT, Kim DW, Nakagawa K, Seto T, Sun X, Ahn MJ, et al. Crizotinib for advanced non-small-cell lung cancer: phase 1 cohorts from the KEYNOTE-021 study. Lung Cancer. 2018;125:273–81. https://doi.org/10.1016/j.lungcan.2018.08.019.

7. Lee HT, Lee JY, Lim H, Lee SH, Moon YJ, Pyo HJ, et al. Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-1 antibodies atezolizumab and durvalumab. Sci Rep. 2017;7(1):15532. https://doi.org/10.1038/s41598-017-06028-8.

8. Daga A, Ansari A, Patel S, Mirza S, Rawal R, Urmia V. Current drugs and drug targets in non-small cell lung cancer: limitations and opportunities. Asian Pac J Cancer Prev. 2015;16(10):4147–56. https://doi.org/10.7314/APJCP.2015.16.10.4147.

9. Sankar K, Gadgkar SM, Qin A. Molecular therapeutic targets in non-small cell lung cancer. Expert Rev Anticancer Ther. 2020;20(8):647–61. https://doi.org/10.1080/14737442.2020.2087156.

10. Zhang S, Bai X, Shan F. The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer. Int Immunopharmacol. 2020;80:106247. https://doi.org/10.1016/j.intimp.2020.0106247.

11. Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv2–17.

12. Postmus PE, Kerr KM, Oudkerk M, Senani S, Waller DA, Vansteenkiste J, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(Suppl 4):iv2–17.

13. Li T, Ling YH, Goldman ID, Perez-Soler R. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res. 2007;13(11):3413–22. https://doi.org/10.1158/1078-0432.CCR-06-2923.

14. Ota A, Gaya Bill, Matsuoka A, Ando Y. Unconventional benefit of combination therapy with gefitinib and pemetrexed in advanced non–small-cell lung cancer. J Clin Oncol. 2017;35(6):691–2. https://doi.org/10.1200/JCO.2016.70.4148.

15. Cheng Y, Muramaki H, Yang FC, He J, Nakagawa K, Kang JH, et al. Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non–small-cell lung cancer with activating epidermal growth factor receptor mutations. J Clin Oncol. 2016;34(27):3258–66. https://doi.org/10.1200/JCO.2016.66.9218.

16. Mok TS, Kim SW, Wu YL, Nakagawa K, Yang JJ, Ahn MJ, et al. Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line gefitinib (impress): overall survival and biomarker analyses. J Clin Oncol. 2017;35(36):4027–34. https://doi.org/10.1200/JCO.2017.73.9250.

17. Hsu PC, Liu CY, Li SH, Huang SH, Wang CL, Kuo CH, et al. Efficacy of platinum-based combination chemotherapy in advanced lung adenocarcinoma harboring sensitive epidermal growth factor receptor (EGFR) mutations with acquired resistance to first-line EGFR tyrosine kinase inhibitor (TKI). Cancer Treat Res Commun. 2016;48:685–99. https://doi.org/10.1016/j.ctarc.2016.07.005.

18. Gadgkar SM, Stevenson JP, Langer CJ, Gandhi L, Borghei H, Patnack A, et al. Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: phase 1 cohorts from the KEYNOTE-021 study. Lung Cancer. 2018;125:273–81. https://doi.org/10.1016/j.lungcan.2018.08.019.

19. Paz-Ares L, Ruif AC, Vicente D, Tafreshi A, Gümü, M, Mazières J, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040–51. https://doi.org/10.1056/NEJMoa1810865.

20. Chang A. Chemotherapy, cheromoresistance and the changing treatment landscape for NSCLC, Lung Cancer. 2011;71(1):1–10. https://doi.org/10.1016/j.jclincan.2011.08.021.

21. Zhang Y, Wang XQ, Liu H, Liu J, Hou W, Lin HS. A multicontour, large-sample, randomized clinical trial on improving the median survival time of advanced non-small cell lung cancer by combination of Ginseng Rg3 and chemotherapy. Zhonghua Zhong Liu Za Zhi. 2018;40(4):295–6. https://doi.org/10.3738/zg.2017.12.0226.

22. Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv2–17.

23. Li T, Liu, Wu, Xu K. Effect of combination of syndrome differentiation depending treatment and chemotherapy on prognostic factors in treating mid-late patients with non-small cell lung cancer. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2003;23(8):575–9. [Article in Chinese]

24. Zhou YZ, Xu L, Li HG, Tian JH, Yao LF, et al. Chemotherapy in conjunction with traditional Chinese medicine for survival of elderly patients with advanced non-small-cell lung cancer: protocol for a randomized double-blind controlled trial. J Integ Med. 2014;12(3):175–81. https://doi.org/10.1016/j.s2095-4964(14)60028-5.
